Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. LEGN
stocks logo

LEGN

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
228.46M
+22.48%
-0.199
+99.4%
277.64M
+73.3%
-0.117
-82.77%
335.94M
+80.11%
0.071
-49.26%
Estimates Revision
The market is revising Upward the revenue expectations for Legend Biotech Corporation (LEGN) for FY2025, with the revenue forecasts being adjusted by 0.16% over the past three months. During the same period, the stock price has changed by 29.00%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.16%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-7.35%
In Past 3 Month
Stock Price
Go Up
up Image
+29.00%
In Past 3 Month
16 Analyst Rating
up Image0
Wall Street analysts forecast LEGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LEGN is 77.05 USD with a low forecast of 54.00 USD and a high forecast of 94.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Buy
1 Hold
0 Sell
Strong Buy
up Image0
Current: 41.590
sliders
Low
54.00
Averages
77.05
High
94.00
up Image0
Current: 41.590
sliders
Low
54.00
Averages
77.05
High
94.00
Morgan Stanley
Overweight
maintain
$80 -> $81
2025-07-10
Reason
Morgan Stanley
Price Target
$80 -> $81
2025-07-10
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on Legend Biotech to $81 from $80 and keeps an Overweight rating on the shares. Year-to-date, large cap pharma and biotech companies have both underperformed given the macro environment, while multiple areas of policy uncertainty remain, including drug pricing dynamics, tariff and transfer pricing exposure, and FDA staffing changes, the analyst tells investors in a research note.
UBS
Ashwani Verma
Buy
downgrade
$60 -> $54
2025-07-02
Reason
UBS
Ashwani Verma
Price Target
$60 -> $54
2025-07-02
downgrade
Buy
Reason
UBS analyst Ashwani Verma lowered the firm's price target on Legend Biotech to $54 from $60 and keeps a Buy rating on the shares. UBS continue to see upside to Legend Biotech stock, but the upside is based on modest growth in Q2, with an acceleration in the second half of 2025, the analyst tells investors in a research note. The stock may continue to be range-bound unless there is a material step-up in the revenue profile of Carvykti, UBS contends.
Truist
Buy
downgrade
$88 -> $71
2025-05-14
Reason
Truist
Price Target
$88 -> $71
2025-05-14
downgrade
Buy
Reason
Truist lowered the firm's price target on Legend Biotech to $71 from $88 and keeps a Buy rating on the shares after its Q1 results. Carvykti sales rose 10% q/q, with U.S. growth modest at 5%, and the firm notes that the more robust acceleration it had hoped for is now likely to come in the second half of the year vs. Q2 previously, the analyst tells investors in a research note.
RBC Capital
Brian Abrahams
Buy
Reiterates
$84
2025-04-22
Reason
RBC Capital
Brian Abrahams
Price Target
$84
2025-04-22
Reiterates
Buy
Reason
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Reiterates
$75
2025-04-16
Reason
HC Wainwright & Co.
Mitchell Kapoor
Price Target
$75
2025-04-16
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Reiterates
$75
2025-04-08
Reason
HC Wainwright & Co.
Mitchell Kapoor
Price Target
$75
2025-04-08
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Legend Biotech Corp (LEGN.O) is -127.73, compared to its 5-year average forward P/E of -29.38. For a more detailed relative valuation and DCF analysis to assess Legend Biotech Corp 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-29.38
Current PE
-127.73
Overvalued PE
-10.26
Undervalued PE
-48.50

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-26.09
Current EV/EBITDA
-210.28
Overvalued EV/EBITDA
-7.92
Undervalued EV/EBITDA
-44.26

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
30.44
Current PS
6.53
Overvalued PS
50.91
Undervalued PS
9.97

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

LEGN News & Events

Events Timeline

(ET)
2025-06-04
09:49:11
Legend immunotherapy offers hope of cure for incurable blood cancer, NYT says
select
link
2025-06-03 (ET)
2025-06-03
10:53:04
Legend Biotech unveils five-year survival data fro CARVYKTI
select
2025-05-13 (ET)
2025-05-13
07:05:05
Legend Biotech reports Q1 EPS (27c), consensus (25c)
select
Sign Up For More Events
Sign Up For More Events

News

Preview
2.0
07-19NASDAQ.COM
Legend Biotech (LEGN) Surges 6.0%: Is This an Indication of Further Gains?

  • Legend Biotech Stock Performance: Legend Biotech's shares rose 6% to $42.13, driven by strong sales of its therapy Carvykti and positive earnings estimate revisions, despite an expected quarterly loss of $0.18 per share.

  • Vanda Pharmaceuticals Update: Vanda Pharmaceuticals saw a 1% increase in stock price, with unchanged EPS estimates indicating a significant year-over-year decline, and both companies hold a Zacks Rank of #3 (Hold).

Preview
7.0
07-09Reuters
Exclusive: US lawmakers renew concerns about GenScript's ties to China

  • Concerns Over GenScript Biotechnology: The U.S. House committee on China has expressed renewed concerns regarding GenScript Biotechnology's ties to China and its potential risks to U.S. intellectual property, prompting requests for updated intelligence from the FBI and national intelligence.

  • Impact on GenScript's Operations: Lawmakers fear that GenScript, which operates in both the U.S. and China, could facilitate the theft of intellectual property and advance China's biotech capabilities, leading to a push for U.S. companies to reduce reliance on such firms.

Preview
4.0
07-08Benzinga
HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $75 Price Target

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, providing real-time intelligence to help them succeed in the stock market.

  • Community and Exclusivity: Joining Benzinga Pro connects users with over 10,000 serious traders and grants access to exclusive stories and insights from Benzinga reporters.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Legend Biotech Corp (LEGN) stock price today?

The current price of LEGN is 41.59 USD — it has decreased -1.28 % in the last trading day.

arrow icon

What is Legend Biotech Corp (LEGN)'s business?

Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

arrow icon

What is the price predicton of LEGN Stock?

Wall Street analysts forecast LEGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LEGN is 77.05 USD with a low forecast of 54.00 USD and a high forecast of 94.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Legend Biotech Corp (LEGN)'s revenue for the last quarter?

Legend Biotech Corp revenue for the last quarter amounts to 195.05M USD, increased 107.52 % YoY.

arrow icon

What is Legend Biotech Corp (LEGN)'s earnings per share (EPS) for the last quarter?

Legend Biotech Corp. EPS for the last quarter amounts to -0.27 USD, increased 68.75 % YoY.

arrow icon

What changes have occurred in the market's expectations for Legend Biotech Corp (LEGN)'s fundamentals?

The market is revising Upward the revenue expectations for Legend Biotech Corporation (LEGN) for FY2025, with the revenue forecasts being adjusted by 0.16% over the past three months. During the same period, the stock price has changed by 29.00%.
arrow icon

How many employees does Legend Biotech Corp (LEGN). have?

Legend Biotech Corp (LEGN) has 2600 emplpoyees as of July 20 2025.

arrow icon

What is Legend Biotech Corp (LEGN) market cap?

Today LEGN has the market capitalization of 7.66B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free